Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyClad Phase 3 Study in Generalized Myasthenia Gravis
jRCT2031240175Phase 3Recruiting
- Sponsor
- Merck KGaA
- Start
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of cladribine in myasthenia gravis (MG) (3 arms), sponsored by Merck KGaA. Primary endpoint: Change from Baseline in MG-ADL score at Week 24. Started Aug 2024; status: recruiting.
02
Drugs
cladribine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2031240175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240175.